Piramal Pharma Ltd

Piramal Pharma Ltd has a debt-to-equity ratio of 0.7, indicating a moderate level of leverage, and a current ratio of 1.51, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -4,032.7 million INR, and its operating cash flow is 16,525.9 million INR, which may indicate challenges in generating sufficient cash from operations to fund its capital expenditures. The company's profitability is underperforming, with a return on equity of -3.99% and a return on assets of -1.81%, both significantly below the industry norms. These metrics suggest that the company is not effectively utilizing its equity and assets to generate profits, which could be a concern for investors. Piramal Pharma Ltd's revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic breakdown. The company's exposure to a single business line may increase its vulnerability to market fluctuations and regulatory changes in the pharmaceutical industry. The company's growth trajectory appears to be mixed. While it has a mean price target of 206.30 INR from analysts, indicating some optimism, its recent financial performance, including a net loss of 3,259.4 million INR, suggests operational challenges. The company's capital expenditures of -8,900.2 million INR indicate significant investment in infrastructure, which may support future growth. The company faces several risk factors, including a net cash position that is negative after subtracting total debt, which could limit its financial flexibility. The risk of dilution is currently low, but the company's negative net income and operating income may necessitate additional financing in the future, potentially leading to share dilution. Recent events, such as the company's financial performance and analyst estimates, suggest a mixed outlook. The company has a mean recommendation of 1.40 from analysts, indicating a generally positive sentiment, but the presence of a net loss and negative returns on equity and assets highlights ongoing challenges.